Technical Analysis for VNDA - Vanda Pharmaceuticals Inc.

Grade Last Price % Change Price Change
grade F 13.58 -0.07% -0.01
VNDA closed down 0.66 percent on Friday, October 18, 2019, on 1.26 times normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Earnings due: Nov 5

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Up
See historical VNDA trend table...

Date Alert Name Type % Chg
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -0.07%
Doji - Bearish? Reversal -0.07%
Stochastic Reached Overbought Strength -0.07%
Weak + Overbought Other -0.07%
Outside Day Range Expansion -0.07%
Weak, Overbought and Reversal Signs Reversal -0.07%
Overbought Stochastic Strength -0.07%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -0.73%
Pocket Pivot Bullish Swing Setup -0.73%
Narrow Range Bar Range Contraction -0.73%

Older signals for VNDA ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Vanda Pharmaceuticals, Inc., a biopharmaceutical company, offers development and commercialization of products for the treatment of central nervous system disorders. The company provides Fanapt, a compound for the treatment of schizophrenia; and VLY-686, a small molecule neurokinin-1 receptor (NK-1R) antagonist that has indications for chemotherapy-induced nausea and vomiting, post-operative nausea and vomiting, alcohol dependence, anxiety, depression, and pruritus. Its product in clinical development includes Tasimelteon, which completed Phase III clinical trials for the treatment of circadian rhythm sleep disorders, as well as completed Phase IIb/III trials for the treatment of major depressive disorder and insomnia. Vanda Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Washington, District of Columbia.
Biopharmaceutical Chemical Compounds Organic Compounds Oncology Chemotherapy Schizophrenia Central Nervous System Disorders Major Depressive Disorder Depression Pyridines Nausea Treatment Of Central Nervous System Disorders Treatment Of Major Depressive Disorder Vomiting Pruritus Sedatives Chemotherapy Induced Nausea Fanapt Iloperidone Insomnia
Is VNDA a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 33.44
52 Week Low 11.83
Average Volume 570,969
200-Day Moving Average 17.0755
50-Day Moving Average 13.8475
20-Day Moving Average 13.2433
10-Day Moving Average 13.11
Average True Range 0.5322
ADX 16.6
+DI 19.6371
-DI 16.4307
Chandelier Exit (Long, 3 ATRs ) 12.6334
Chandelier Exit (Short, 3 ATRs ) 13.9135
Upper Bollinger Band 14.0225
Lower Bollinger Band 12.4641
Percent B (%b) 0.72
BandWidth 11.76746
MACD Line -0.0997
MACD Signal Line -0.2055
MACD Histogram 0.1058
Fundamentals Value
Market Cap 609.62 Million
Num Shares 44.9 Million
EPS -0.23
Price-to-Earnings (P/E) Ratio -59.09
Price-to-Sales 4.05
Price-to-Book 4.81
PEG Ratio -2.09
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 14.10
Resistance 3 (R3) 14.10 13.93 14.02
Resistance 2 (R2) 13.93 13.80 13.93 13.99
Resistance 1 (R1) 13.76 13.72 13.68 13.76 13.96
Pivot Point 13.59 13.59 13.55 13.59 13.59
Support 1 (S1) 13.42 13.46 13.34 13.42 13.22
Support 2 (S2) 13.25 13.38 13.25 13.19
Support 3 (S3) 13.08 13.25 13.17
Support 4 (S4) 13.08